CTMX Varseta-M and CX-801 progress in phase I oncology trials
Varseta-M, an EpCAM-targeting ADC, is advancing in phase I for late-line colorectal cancer with Fast Track status and plans for pivotal studies and expansion. CX-801, a masked interferon alfa-2b, is progressing in phase I for late-line melanoma.
Varseta-M, a first-in-class EpCAM-targeting ADC, is advancing through phase I in late-line colorectal cancer with Fast Track status and plans for pivotal studies and expansion into new tumor types. CX-801, a masked interferon alfa-2b, is progressing in phase I for late-line melanoma, with early bio…